Neuroendocrine tumours: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

23 of 23+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €268,569· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €4,574,378· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norway· EU contribution €4,773,849· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxembourg· EU contribution €14,837,694· until Dec 2029· 13 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  NET ZERO PATHWAY RESEARCH THROUGH INTEGRATED ASSESSMENT MODEL ADVANCEMENTS (PRISMA)

  Fondazione Centro Euro-Mediterraneosui Cambiamenti Climatici· Lecce, Italy· EU contribution €4,457,810· until Dec 2026· 10 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  TRANSNATIONAL NETWORK OF NATIONAL CONTACT POINTS (NCPS) FOR WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA (NCP_WIDERA.NET)

  Narodowe Centrum Badan I Rozwoju· Warszawa, Poland· EU contribution €8,000,000· until Mar 2027· 28 countries

7 of 7 running projects, newest first. Listed amounts together: €37.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· Hutchmed· Updated 8 May 2025

  “Study terminated by sponsor”Registry text, quoted unchanged. Source

• Withdrawn

  Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

  NCT05582031· Translational Research in Oncology· Updated 7 Jun 2023

  “Study never started/ will not proceed.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

  NCT02628067· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 201
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Associations Between Circulating Metabolites and Skin Cancer: A Bidirectional Two-Sample Mendelian Randomization Study.

  Cancer Med, Oct 2026

• Investigating the causal association between liver condition and melanoma: evidence from the National Health and Nutrition Examination Survey and Mendelian randomization.

  Melanoma Res, Jul 2026

• Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.

  Can J Gastroenterol Hepatol, Dec 2025

• Statin medication and Malignant melanoma of skin: A Mendelian randomization study.

  Asian J Surg, Aug 2023

• Circulating vitamin D concentration and risk of 14 cancers: a bidirectional Mendelian randomization study.

  J Cancer Res Clin Oncol, Aug 2023

• Is there a causal relationship between vitamin D and melanoma risk? A Mendelian randomization study.

  Br J Dermatol, Sept 2019

See which targets of this disease your abstract mentions, and go to the people working on them.